SCHEMBL9963305

SCHEMBL9963305

COc1ccc2c(c1)C(=O)CC1(CCN(C(C)C)CC1)S2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RYR2 Q92736 3/20 0.40
KDM4E B2RXH2 4/20 0.39
HTT P42858 1/20 0.39
KLK7 P49862 1/20 0.39
ALDH1A1 P00352 3/20 0.38
MAPT P10636 2/20 0.37
TP53 P04637 1/20 0.37
POLB P06746 1/20 0.37
MMP1 P03956 1/20 0.37
MMP9 P14780 1/20 0.37
MMP13 P45452 1/20 0.37
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HTR2C P28335 2/20 0.35
LMNA P02545 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2B P41595 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12836267 0.88 RYR2 (0.42) RYR2KDM4EHTTKLK7ALDH1A1
SCHEMBL13339972 0.81 RYR2 (0.45) RYR2KDM4EHTTKLK7ALDH1A1
SCHEMBL9963318 0.81 CYP2D6 (0.42) KDM4EHTTALDH1A1MAPTPOLB
Hydrochloric Acid SCHEMBL3493083 0.80 RYR2 (0.44) RYR2KDM4EHTTKLK7ALDH1A1
SCHEMBL3493951 0.80 MEN1 (0.43) KDM4EHTTALDH1A1MAPTSMN1; SMN2
SCHEMBL3493950 0.80 MEN1 (0.43) KDM4EHTTALDH1A1MAPTSMN1; SMN2
SCHEMBL1140756 0.76 ALDH1A1 (0.47) RYR2KDM4EHTTKLK7ALDH1A1
SCHEMBL9963308 0.72 KDM4E (0.38) RYR2KDM4EHTTKLK7ALDH1A1
SCHEMBL8118067 0.68 RYR2 (0.56) RYR2KDM4EHTTALDH1A1PDE3B
SCHEMBL9963148 0.67 KDM4E (0.53) KDM4EHTTKLK7ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 RYR2 150/4885KDM4E 3804/4885HTT 4256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.